Simulations Plus

Learn about new, improved, and enhanced features to drive advances to in vitro-in vivo extrapolation (IVIVE) for permeability, hepatocyte, skin penetration, and release assay systems.

Systemic sclerosis (SSc), also known as scleroderma, is a rare connective tissue and autoimmune disease associated with inflammation and fibrosis of the skin and/or internal organs.

The focus of this webinar will be to discuss how physiological differences between fasted and fed states have been incorporated into mechanistic absorption (MAM) and physiologically based pharmacokinetic (PBPK) models to predict positive and negative food effects.

Based on the recent publication from AAPS PharmSci Tech, this 60-minute webinar will showcase an example of the use of GastroPlus® to assess the risk and pharmacokinetic relevance of different solubility and particle size between crystal forms of a poorly water-soluble antihypertensive drug, for diverse physiological conditions.

Development of formulation and setting dissolution test specifications for IR tablets based on PBPK modeling & simulation – amiodarone as a case example

Dose recommendations are usually established using data driven approaches, i.e., population modeling & simulation...

PBPK models that describe drug performance following pulmonary administration, like the PCAT™ model within GastroPlus(R), have appeared more recently, yet few pieces of literature report on their use.

The latest version of GastroPlus® has the most innovative & integrative software improvements to accelerate drug development through continued collaborations with several large pharmaceutical companies and the U.S. FDA!

PBPK modeling gives birth to a new application!

Understanding drug and drug formulation performance in relation to the prandial conditions is essential for ensuring the safety and efficacy of products to be administered to pediatric patients, especially newborns...

Quantitative systems pharmacology (QSP) modeling enables better drug development decisions through a more advanced understanding of the disease area of inter

IPFsym® is a mechanistic, mathematical model for QSP of idiopathic pulmonary fibrosis (IPF) that can be used to predict efficacy for potential treatments.

The central idea behind the “learn and confirm” paradigm is to emphasize the learning part of R&D and then intelligently apply what has been learned to the design of clinical trials.

DDDPlus is a state-of-the-art simulation platform for in vitro dissolution.

What if we could reduce the size of a phase III study from 400 to 80 subjects and make it twice as short? Thanks to model-informed clinical trial design, it's possible!

NAFLDsym is a quantitative systems pharmacology (QSP) modeling software to support the development of treatments for non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

What do NURTEC™ ODT, TURALIO®, lixivaptan, solithromycin, JYNARQUE®, VEKLURI®, and UBRELVY® have in common?